Tag:

Pascal Soriot

Latest Headlines

Latest Headlines

DOJ clears AstraZeneca for a U.S. Brilinta takeoff

The U.S. Department of Justice closed out its probe of a key Brilinta trial--and without further ado. No additional label warnings. And certainly no forced withdrawal from the U.S. market.

Apparently confident AstraZeneca CEO socks $3.4M into company shares

Pascal Soriot has raised the stakes on AstraZeneca's turnaround. The chief executive plunked down $3.4 million to buy more of his company's shares. 

Smells like team spirit: AstraZeneca CEO says Pfizer fight has it pumped to perform

Pascal Soriot says confidently that AstraZeneca will make its forecast of $45 billion in sales by 2023, the one it trotted out during its fight with Pfizer to convince shareholders it was best going it alone. 

Sweden politely excoriates Pfizer over megamerger with AstraZeneca

As the May 26 deadline for Pfizer to sweeten its $106 billion offer for AstraZeneca draws closer, a bevy of Swedish officials are now echoing the British government's concern that the deal will be bad for European business.

British PM wants more Pfizer promises, but pharma's merger vows are fleeting

Reuters reports that British Prime Minister David Cameron is now demanding stronger guarantees that Pfizer's buyout of AstraZeneca won't decimate the country's science community and leave a host of employees jobless.

AstraZeneca shareholders pitch a fit about pay

AstraZeneca CEO Pascal Soriot saw his pay fall last year along with the company's fortunes but that didn't keep large blocks of shareholders from displaying their distaste for the company's compensation outlay for him and board members.

AstraZeneca CEO jumps into asset-sale fray to 'focus on what we do well'

In announcing first-quarter earnings Thursday, AstraZeneca CEO Pascal Soriot sounded as if he'd been reading the deluge of trend stories analyzing pharma's latest spate of M&A. In fact, he's ready to participate, with a couple of sales/spinoffs together worth about $15 billion, according to analysts

AstraZeneca continues to chop back, spotlights immuno-oncology PhIII

AstraZeneca is continuing its campaign to refashion its image as it tries to shake off past setbacks and unsuccessful units and turn analysts' attention to its brightest pipeline prospects, particularly in cancer.

Soriot notches a bigger bonus, but total $5.5M in pay is no record breaker

AstraZeneca CEO Pascal Soriot scored a big increase in bonus for 2013, but his total not only falls short of last year's, but pales by comparison with the biggest in Big Pharma. And his predecessor David Brennan's pay beats the total, too.

AstraZeneca adds a combo research pact to a flurry of new antibiotics deals

When AstraZeneca CEO Pascal Soriot unveiled the company's new R&D strategy a little less than a year ago, the antibiotics research field was downgraded in the revamp--part of a general retreat by the industry as superbugs presented an ever-growing threat around the world. But the pharma heavyweight didn't abandon antibiotics.